The fact
The French biopharmaceutical company targets metabolic and liver diseases.
This milestone could boost investor confidence and stabilize its stock.
Click the link to read an article on the topic:
The French biopharmaceutical company targets metabolic and liver diseases.
This milestone could boost investor confidence and stabilize its stock.